Webster Bank N. A. bought a new position in Crispr Therapeutics AG (NASDAQ:CRSP) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 420 shares of the company’s stock, valued at approximately $26,000.
Several other hedge funds have also modified their holdings of CRSP. Perigon Wealth Management LLC bought a new position in Crispr Therapeutics during the fourth quarter valued at about $278,000. Farmers & Merchants Trust Co of Chambersburg PA bought a new position in Crispr Therapeutics during the fourth quarter valued at about $26,000. Millennium Management LLC bought a new position in Crispr Therapeutics during the third quarter valued at about $4,366,000. Orbimed Advisors LLC bought a new position in Crispr Therapeutics during the third quarter valued at about $21,167,000. Finally, Granahan Investment Management Inc. MA increased its stake in Crispr Therapeutics by 8.3% during the third quarter. Granahan Investment Management Inc. MA now owns 34,582 shares of the company’s stock valued at $1,418,000 after acquiring an additional 2,655 shares during the period. Institutional investors and hedge funds own 49.83% of the company’s stock.
In other Crispr Therapeutics news, President Rodger Novak sold 33,618 shares of the stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total value of $2,353,260.00. Following the sale, the president now directly owns 33,618 shares in the company, valued at approximately $2,353,260. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Pablo J. Cagnoni sold 7,500 shares of the stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $62.00, for a total transaction of $465,000.00. Following the completion of the transaction, the director now directly owns 7,500 shares in the company, valued at approximately $465,000. The disclosure for this sale can be found here. Over the last three months, insiders have sold 56,118 shares of company stock valued at $3,620,760. 21.40% of the stock is currently owned by insiders.
Shares of NASDAQ:CRSP opened at $58.12 on Wednesday. The firm’s fifty day moving average is $64.11 and its 200-day moving average is $52.37. Crispr Therapeutics AG has a 52 week low of $29.34 and a 52 week high of $74.00. The firm has a market cap of $3.22 billion, a PE ratio of -126.35 and a beta of 3.20. The company has a debt-to-equity ratio of 0.06, a quick ratio of 8.32 and a current ratio of 8.32.
Crispr Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Monday, October 28th. The company reported $2.40 earnings per share for the quarter, beating the consensus estimate of ($0.95) by $3.35. The firm had revenue of $211.93 million for the quarter, compared to analyst estimates of $6.32 million. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. Sell-side analysts forecast that Crispr Therapeutics AG will post 0.65 EPS for the current year.
Several equities research analysts have recently weighed in on CRSP shares. Chardan Capital reiterated a “buy” rating and issued a $72.50 price objective on shares of Crispr Therapeutics in a research note on Monday, November 18th. Oppenheimer increased their price target on Crispr Therapeutics from $65.00 to $80.00 and gave the company an “outperform” rating in a research note on Monday, November 25th. William Blair upgraded Crispr Therapeutics from a “market perform” rating to an “outperform” rating in a report on Tuesday, November 19th. ValuEngine downgraded shares of Crispr Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, January 3rd. Finally, Zacks Investment Research downgraded shares of Crispr Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, September 30th. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rating and twelve have assigned a buy rating to the company. The company has an average rating of “Buy” and an average price target of $71.38.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Featured Article: Google Finance Portfolio
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.